<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="Learn about CDKL5 Deficiency Disorder, AAV9 gene therapy treatment, research team, and our mission to bring hope to 500+ families worldwide.">
    <title>About CDKL5 Deficiency Disorder & Gene Therapy Research</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/colors.css">
    <style>
        /* Unified Color System Overrides for About Page */
        
        /* Page background - warm cream */
        body {
            background: var(--bg-page) !important;  /* Warm cream */
        }
        
        .section {
            background: transparent !important;
        }
        
        /* First section - warm pastel */
        .section:first-of-type {
            background: var(--section-warm) !important;  /* Soft peach */
            padding: 4rem 1.5rem;
        }
        
        /* Alternating section backgrounds */
        .section:nth-of-type(even) {
            background: var(--section-cool) !important;  /* Soft blue */
            padding: 4rem 1.5rem;
        }
        
        /* Remove badge or make it subtle */
        .badge {
            background: #f0f4ff !important;
            color: var(--heading-secondary) !important;
            padding: 0.5rem 1rem;
            border-radius: 50px;
            font-size: 0.85rem;
            font-weight: 600;
            display: inline-block;
            margin-bottom: 1rem;
        }
        
        /* Page title - dark blue H1 */
        h1 {
            color: var(--heading-primary) !important;  /* Dark blue */
            font-size: 2.5rem;
            font-weight: 700;
        }
        
        /* Section titles - softer blue H2 */
        h2 {
            color: var(--heading-secondary) !important;  /* Softer blue */
            font-size: 2rem;
            font-weight: 700;
        }
        
        /* Card titles - softer blue H3 */
        h3 {
            color: var(--heading-secondary) !important;  /* Softer blue */
            font-weight: 700;
        }
        
        /* Mission statement */
        .mission-statement {
            background: var(--section-accent) !important;  /* Soft lavender */
            padding: 2rem;
            border-left: 4px solid var(--primary-orange) !important;
            border-radius: 8px;
            margin: 2rem 0;
        }
        
        .mission-statement p {
            color: #333 !important;
            font-size: 1.25rem;
            font-weight: 600;
            margin: 0;
        }
        
        /* Cards - Change from pink to white */
        .card {
            padding: 2rem;
            background: #ffffff !important;
            border-radius: 12px;
            box-shadow: 0 2px 16px rgba(0,0,0,0.08) !important;
            transition: all 0.3s;
        }
        
        .card:hover {
            transform: translateY(-4px);
            box-shadow: 0 4px 20px rgba(0,0,0,0.12) !important;
        }
        
        .card h3 {
            color: #303f9f !important;
            font-size: 1.2rem;
            font-weight: 700;
            margin-bottom: 0.75rem;
        }
        
        .card p, .card ul {
            color: #666666 !important;
            line-height: 1.6;
        }
        
        /* Group titles */
        .group-title {
            color: var(--heading-secondary) !important;  /* Softer blue */
            font-size: 1.5rem;
            font-weight: 700;
            margin-bottom: 1.5rem;
        }
        
        /* Page background */
        body {
            background: var(--bg-page) !important;  /* Warm cream */
        }
        
        .section {
            background: transparent !important;
        }
        
        /* Info list */
        .info-list {
            color: #666666 !important;
        }
        
        .info-list li {
            margin-bottom: 0.75rem;
            line-height: 1.6;
        }
    </style>
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-XXXXXXX-X"></script>
    <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);} // minimal GA placeholder
        gtag('js', new Date());
        gtag('config', 'UA-XXXXXXX-X');
    </script>
</head>
<body>
    <div data-include="inc/header.html"></div>

    <main>
        <div class="container">
            <section class="section fade-in">
                <span class="badge">Root-cause therapy</span>
                <h1>About our CDKL5 AAV9 program</h1>
                <p>We are a coalition of families, clinicians, and drug developers partnering to deliver a one-time gene therapy that addresses the fundamental deficit driving CDKL5 Deficiency Disorder (CDD). By transporting a functional CDKL5 gene directly into neurons, we aim to restore protein expression, stabilize circuitry, and reclaim developmental potential.</p>
            </section>

            <div class="mission-statement">
                <p>We aren't waiting for a cure for CDKL5, we are making it happen.</p>
            </div>

            <section class="section fade-in" aria-labelledby="mechanism-heading">
                <h2 id="mechanism-heading">How the therapy works</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Targeted delivery</h3>
                        <p>Our therapy uses a special carrier to deliver a healthy <strong>CDKL5</strong> gene directly to brain cells, reaching key areas like the cortex and hippocampus.</p>
                    </article>
                    <article class="card">
                        <h3>Restoring Hope</h3>
                        <p>Once inside, the gene helps produce a vital protein that supports brain function, reduces seizures, and boosts development for kids with <strong>CDKL5 Deficiency Disorder</strong>.</p>
                    </article>
                    <article class="card">
                        <h3>Long-Lasting Effect</h3>
                        <p>This treatment is designed to work steadily over time, offering lasting benefits without altering a child's natural DNA.</p>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="team-heading">
                <h2 id="team-heading">CDKL5 Gene Therapy Team</h2>

                <div class="team-group">
                    <h3 class="group-title">Clinical</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Nalin Gupta (University of California, San Francisco)</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Adam Numis (University of California, San Francisco)</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">Preclinical</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Jacinthe Gingras</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Kruti Patel</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Ajay Bhargava (Shakti Bioresearch Labs)</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Matthew Simon (Jackson Laboratory)</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Vincent Pons (Jackson Laboratory)</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">Design</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Lester Suarez</h3>
                        </article>
                        <article class="card">
                            <h3>Ilya Musavey</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">Manufacturing</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Paul Herzich</h3>
                        </article>
                        <article class="card">
                            <h3>Sarah Caffey (MaticaBio)</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">Scientific Advisors</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Michael Templin (Charles River Laboratory)</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Cecilia Lo (University of Pittsburgh)</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">Regulatory</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Tim Cote</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Sangeeta Joshi</h3>
                        </article>
                    </div>
                </div>

                <div class="team-group">
                    <h3 class="group-title">India Clinical Team</h3>
                    <div class="card-grid">
                        <article class="card">
                            <h3>Dr. Sheffali Gulati</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Lokesh Lingappa</h3>
                        </article>
                        <article class="card">
                            <h3>Dr. Prasanthi Aripiralla</h3>
                        </article>
                    </div>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="leadership-heading">
                <h2 id="leadership-heading" style="text-align: center;">Detailed Scientific Team Biosketches</h2>
                <p style="text-align: center; max-width: 800px; margin: 0 auto 3rem; font-size: 1.1rem; color: #666;">
                    Comprehensive NIH-format biosketches for key members of our scientific leadership team, including their positions, contributions to science, and research support.
                </p>

                <div class="biosketches-simple">
                    
                    <!-- Dr. Nalin Gupta -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Nalin Gupta, MD, PhD</h3>
                            <div class="bio-subtitle">Principal Investigator | Professor of Neurological Surgery and Pediatrics, UCSF</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Nalin Gupta, Professor of Neurological Surgery and Pediatrics at UCSF and Chief of the Division of Pediatric Neurosurgery, is ideally suited to lead the CDKL5 gene therapy project as Principal Investigator. With over 20 years of experience in pediatric neurosurgery, he specializes in treating neurological disorders such as epilepsy, brain tumors, and congenital anomalies.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>His leadership in a phase I gene therapy trial for AADC deficiency, a condition similar to CDKL5 deficiency due to loss of functional protein, equips him to oversee study design, in vivo surgical delivery, and coordination with the research team. Dr. Gupta's expertise ensures the preclinical development of the AAV9.Syn.hCDKL5 vector will meet rigorous safety and efficacy standards, advancing toward FDA IND submission. His role as Principal Investigator of the UCSF Brain Tumor Research Center and his involvement in national clinical studies further underscore his capability to drive this project forward.</p>
                            </div>
                            <div class="bio-section">
                                <h4>B. Positions and Honors</h4>
                                <p><strong>Positions:</strong></p>
                                <ul>
                                    <li>2000–Present: Professor, Departments of Neurological Surgery and Pediatrics, UCSF</li>
                                    <li>2000–Present: Chief, Division of Pediatric Neurosurgery, UCSF</li>
                                    <li>2000–Present: Principal Investigator, Brain Tumor Research Center, UCSF</li>
                                    <li>1998–2000: Clinical Associate, Section of Neurosurgery, University of Chicago</li>
                                </ul>
                                <p><strong>Honors:</strong></p>
                                <ul>
                                    <li>TP Morley Resident Research Award, University of Toronto</li>
                                    <li>Multiple teaching awards during residency, University of Toronto</li>
                                </ul>
                            </div>
                            <div class="bio-section">
                                <h4>C. Contributions to Science</h4>
                                <p><strong>1. Advancements in Fetal Surgery for Myelomeningocele</strong></p>
                                <p>Dr. Gupta led the neurosurgical component of the Management of Myelomeningocele Study (MOMS), demonstrating that prenatal surgery reduces the need for shunting and improves motor outcomes compared to postnatal repair. This work has established prenatal surgery as a standard of care for selected cases.</p>
                                <ul>
                                    <li>Adzick, N. S., et al. (2011). A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele. <em>New England Journal of Medicine</em>, 364(11), 993–1004. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1014379" target="_blank" rel="noopener noreferrer">[NEJM]</a></li>
                                </ul>
                                <p><strong>2. Pioneering Gene Therapy for Neurological Disorders</strong></p>
                                <p>As clinical Principal Investigator, Dr. Gupta contributed to a phase I study evaluating gene therapy for AADC deficiency, showing improvements in motor and cognitive functions via AAV2-hAADC delivery to the midbrain. This experience is directly applicable to the CDKL5 project.</p>
                                <ul>
                                    <li>Pearson, T. S., et al. (2021). Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. <em>Nature Communications</em>, 12, 4251. <a href="https://www.nature.com/articles/s41467-021-24524-8" target="_blank" rel="noopener noreferrer">[Nature]</a></li>
                                </ul>
                                <p><strong>3. Research on Brain Tumor Progression</strong></p>
                                <p>Dr. Gupta's laboratory investigates inflammation's role in pediatric brain tumor progression, particularly medulloblastoma, identifying novel therapeutic targets to improve treatment outcomes.</p>
                                <ul>
                                    <li>Chinnam, D., et al. (2023). Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma. <em>Applied Immunohistochemistry & Molecular Morphology</em>, 31(8), 561–568. <a href="https://pubmed.ncbi.nlm.nih.gov/37471625/" target="_blank" rel="noopener noreferrer">[PubMed]</a></li>
                                </ul>
                            </div>
                            <div class="bio-section">
                                <h4>D. Research Support</h4>
                                <p><strong>Ongoing:</strong></p>
                                <ul>
                                    <li>NIH R01CA246722 (07/01/2020–06/30/2025): Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects. Role: Co-Principal Investigator.</li>
                                </ul>
                                <p><strong>Completed:</strong></p>
                                <ul>
                                    <li>V Foundation 02016-007 (04/15/2016–10/15/2019): Convection-enhanced delivery of nanoliposomal CPT-11 for DIPG. Role: Co-Investigator.</li>
                                    <li>NIH K08NS055061 (04/19/2006–02/28/2011): Macrophage and Microglial Activation in Glioma-Associated Inflammation. Role: Principal Investigator.</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <!-- Dr. Kruti Patel -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Kruti Patel, PhD</h3>
                            <div class="bio-subtitle">AAV Immunology Lead | Associate Director of AAV Immunology, Solid Biosciences</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Kruti Patel is a distinguished scientist specializing in gene therapy development, with a focus on the immunological challenges of AAV vectors. As Associate Director of AAV Immunology at Solid Biosciences, she leads efforts to optimize gene therapy platforms for enhanced safety and efficacy.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>Her career includes significant achievements in advancing therapeutic candidates through preclinical development to IND submission. At Pfizer, Dr. Patel spearheaded non-human primate (NHP) studies to develop immunosuppression strategies for AAV gene therapy, addressing critical barriers to treatment success. She also led a biology team in transitioning a recombinant protein program to the IND filing stage, showcasing her regulatory expertise. At Homology Medicines, Inc., she drove a neuroscience gene therapy program from exploratory research to IND readiness, conducting proof-of-concept studies that led to a clinical candidate nomination. For the CDKL5 gene therapy project, Dr. Patel will apply her expertise to optimize the immunological profile of the AAV9.Syn.hCDKL5 vector, designing studies to minimize adverse immune responses and maximize therapeutic benefit. Her skills in assay development, immunogenicity assessment, and cross-functional leadership are critical to achieving FDA IND submission and advancing treatment for CDKL5 deficiency disorder (CDD).</p>
                            </div>
                            <div class="bio-section">
                                <h4>B. Positions and Honors</h4>
                                <p><strong>Positions:</strong></p>
                                <ul>
                                    <li>2023–Present: Associate Director, AAV Immunology, Solid Biosciences</li>
                                    <li>2022–2023: Principal Scientist, Pfizer</li>
                                    <li>2020–2022: Scientist II, Homology Medicines, Inc.</li>
                                    <li>2018–2020: Scientist I, Homology Medicines, Inc.</li>
                                    <li>2017–2018: Postdoctoral Fellow, Broad Institute of MIT and Harvard</li>
                                    <li>2016–2018: Research Fellow, Harvard Medical School</li>
                                    <li>2011–2016: Ph.D. in Molecular and Translational Medicine, Boston University School of Medicine</li>
                                </ul>
                                <p><strong>Honors:</strong></p>
                                <ul>
                                    <li>Harvard Business School Leadership Essentials Program, 2023</li>
                                </ul>
                            </div>
                            <div class="bio-section">
                                <h4>C. Contributions to Science</h4>
                                <p><strong>1. Development of Gene Therapy for Hunter Syndrome</strong></p>
                                <p>Dr. Patel contributed to HMI-203, an investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Her work involved preclinical studies to evaluate efficacy and safety, advancing the therapy toward clinical trials.</p>
                                <ul>
                                    <li>Patel, K. R., et al. (2021). HMI-203: Investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. <em>Molecular Genetics and Metabolism</em>, 132(2), S82. <a href="https://www.researchgate.net" target="_blank" rel="noopener noreferrer">[ResearchGate]</a></li>
                                </ul>
                                <p><strong>2. Leadership in Preclinical Gene Therapy Development</strong></p>
                                <p>At Homology Medicines, Inc., Dr. Patel led IND-enabling studies for a neuroscience gene therapy program. She developed in vitro and tissue-based assays for target validation and proof-of-concept studies, successfully nominating a clinical candidate and advancing it to the IND stage through cross-functional collaboration.</p>
                                <p><strong>3. Advancements in Immunosuppression for Gene Therapy</strong></p>
                                <p>At Pfizer, Dr. Patel led NHP studies to identify immunosuppression strategies for AAV gene therapy platforms. Her work addressed immune responses that limit treatment efficacy, designing and analyzing experiments to enhance therapy safety and effectiveness.</p>
                                <p><strong>4. Research on Neuro-Immune Interactions</strong></p>
                                <p>As a postdoctoral fellow at the Broad Institute and Harvard Medical School, Dr. Patel investigated microglia's role in Alzheimer's disease pathology. She developed high-throughput screening methods to study gene functions related to amyloid-beta uptake, enhancing understanding of neuro-immune crosstalk in neurodegenerative disorders.</p>
                            </div>
                        </div>
                    </div>

                    <!-- Dr. Jacinthe Gingras -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Jacinthe Gingras, PhD</h3>
                            <div class="bio-subtitle">Scientific Advisor</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Jacinthe Gingras, PhD, serves as Scientific Advisor for the CDKL5 Gene Therapy program, bringing deep biotechnology leadership and scientific strategy experience to the team. She has held senior scientific leadership roles, including as Vice President of Discovery Research where she guided multidisciplinary research teams and translational science initiatives, successfully bringing multiple gene therapies for neurological diseases to the clinic.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>Dr. Gingras's breadth of experience in therapeutic development, strategic program planning, and scientific innovation helps ensure that our approach to CDKL5 gene therapy is informed by both rigorous science and practical pathways toward clinical translation.</p>
                            </div>
                        </div>
                    </div>

                    <!-- Paul Herzich (Updated) -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Paul Herzich</h3>
                            <div class="bio-subtitle">Chief Technology Officer, Solid Biosciences</div>
                        </div>
                        <div class="bio-summary">
                            <p>Paul Herzich is Chief Technology Officer at Solid Biosciences and a recognized leader in gene therapy manufacturing and CMC strategy, with over 20 years of experience advancing biologics and genetic medicines from early development through clinical and commercial stages. He leads technical operations for AAV-based gene therapies, overseeing process and analytical development, quality control, manufacturing, and supply chain.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>Paul has held senior leadership roles at AavantiBio, BridgeBio, LogicBio Therapeutics, and Pfizer, where he built and scaled cGMP manufacturing platforms to support IND and clinical programs. His expertise includes CMC strategy, regulatory readiness, and the production of high-quality clinical-grade AAV vectors. For the CDKL5 gene therapy program, Paul's experience is critical to ensuring scalable, compliant, and reliable vector manufacturing. His leadership helps bridge early scientific innovation with real-world clinical delivery for patients and families.</p>
                            </div>
                        </div>
                    </div>

                    <!-- Dr. Ajay Bhargava -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Ajay Bhargava, PhD</h3>
                            <div class="bio-subtitle">Founder & Chief Scientific Officer, Shakti Bioresearch Labs</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Ajay Bhargava is the Founder and Chief Scientific Officer of Shakti Bioresearch Labs, a contract research organization focused on enabling preclinical drug discovery and IND-enabling studies. He earned his PhD from the Indian Institute of Science, Bangalore, and completed post-doctoral work at Yale University, where he gained expertise in molecular target identification, assay development, and therapeutic discovery across diverse disease areas.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>At Bayer Corporation, Dr. Bhargava led cross-functional preclinical teams and contributed to projects that progressed toward Phase I clinical development, demonstrating deep experience in translational research and regulatory readiness. His leadership in assay design, model development, and preclinical strategy provides valuable support to the CDKL5 gene therapy program by strengthening our ability to generate robust, IND-supporting preclinical data and to efficiently address key scientific questions as we advance toward clinical milestones.</p>
                            </div>
                        </div>
                    </div>

                    <!-- Dr. Lester Suarez -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Lester Suarez, PhD</h3>
                            <div class="bio-subtitle">Vector Development Lead | Vice President of Research and Development, M34, Inc.</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Lester Suarez, Vice President of Research and Development at M34, Inc., and Affiliate Faculty at CSU College of Veterinary Medicine and Biomedical Sciences, is a leading expert in AAV gene therapy and virology. With over 15 years of experience, he has advanced therapeutic candidates for rare diseases, including neurological disorders.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>At AskBio, as Senior Director of Innovation, he led R&D efforts for AAV-based gene therapies, building on the pioneering work of Dr. Richard Jude Samulski. His expertise spans viral vector design, preclinical animal models, and translational research, as demonstrated in his work on hepatitis and oncolytic virotherapies. As a member of the ARDAT consortium and the Dravet Syndrome Foundation Spain's Scientific Evaluation Board, Dr. Suarez has shaped gene therapy strategies for rare diseases. For the CDKL5 gene therapy project, Dr. Lester Suarez has done gene therapy vector development, vector delivery optimization and preclinical testing, ensuring the therapy's efficacy and safety. Dr. Suarez's contributions help bridge the gap between preclinical studies development and clinical application.</p>
                            </div>
                            <div class="bio-section">
                                <h4>B. Positions and Honors</h4>
                                <p><strong>Positions:</strong></p>
                                <ul>
                                    <li>2024–Present: Vice President, Research and Development, M34, Inc., North Carolina, USA</li>
                                    <li>2024–Present: Affiliate Faculty, CSU College of Veterinary Medicine and Biomedical Sciences, Fort Collins, Colorado, USA</li>
                                    <li>2020–2025: Member, Scientific Evaluation Board, Dravet Syndrome Foundation Spain, Spain</li>
                                    <li>2021–2024: Member, ARDAT Consortium</li>
                                    <li>2023–2024: Senior Director of Innovation, Asklepios BioPharmaceutical, Inc. (AskBio), Raleigh-Durham, North Carolina, USA</li>
                                    <li>2022–2023: Director of Innovation, AskBio, North Carolina, USA</li>
                                    <li>2019–2022: Director, Research & Development, AskBio, Raleigh-Durham, North Carolina, USA</li>
                                    <li>2019: Senior Research Scientist, AskBio, Raleigh-Durham, North Carolina, USA</li>
                                    <li>2018–2019: Postdoctoral Research Associate, UC San Diego School of Medicine, La Jolla, California, USA</li>
                                    <li>2015–2018: Postdoctoral Research Associate, Salk Institute for Biological Studies, La Jolla, California, USA</li>
                                    <li>2011–2015: Graduate Research Teaching Assistant, University of Navarra, Pamplona, Navarra, Spain</li>
                                    <li>2010–2015: Researcher PhD Student, Cima Universidad de Navarra, Pamplona, Navarra, Spain</li>
                                    <li>2014: Visiting PhD Student, University of Heidelberg, Heidelberg, Germany</li>
                                    <li>2006–2009: Research Assistant Graduate Student, Centro de Ingeniería Genética y Biotecnología, Havana, Cuba</li>
                                </ul>
                            </div>
                            <div class="bio-section">
                                <h4>C. Contributions to Science</h4>
                                <p><strong>1. Advancements in AAV Gene Therapy</strong></p>
                                <p>At AskBio, Dr. Suarez led innovation in AAV-based gene therapies for rare diseases, optimizing viral vectors for enhanced delivery and efficacy. His work contributed to the advancement of therapeutic candidates toward clinical trials, building on AskBio's pioneering AAV platform.</p>
                                <p><strong>2. Preclinical Models for Viral Therapies</strong></p>
                                <p>During his postdoctoral research at the Salk Institute and UC San Diego, Dr. Suarez developed preclinical models for oncolytic virotherapies and flavivirus infections. His studies on adenovirus and molecular virology provided insights into host-pathogen interactions, informing therapeutic design.</p>
                                <p><strong>3. Gene Therapy for Viral Hepatitis</strong></p>
                                <p>As a PhD student at Cima Universidad de Navarra and a visiting researcher at the University of Heidelberg, Dr. Suarez investigated HBV and HDV using animal models and Trojan horse virus strategies. His work advanced gene therapy approaches for viral hepatitis, contributing to novel therapeutic strategies.</p>
                                <p><strong>4. Therapeutic Cancer Vaccines</strong></p>
                                <p>At the Centro de Ingeniería Genética y Biotecnología, Dr. Suarez developed viral vector-based cancer vaccines using transgenic mice models. His research laid the groundwork for innovative immunotherapies targeting cancer.</p>
                            </div>
                        </div>
                    </div>

                    <!-- Dr. Tim Cote -->
                    <div class="biosketch-simple">
                        <div class="bio-header-simple">
                            <h3>Dr. Tim Cote, MD, MPH</h3>
                            <div class="bio-subtitle">Regulatory Affairs Lead | CEO, Only Orphans Coté LLC & Partner, Porcine Preclinical Partners</div>
                        </div>
                        <div class="bio-summary">
                            <p>Dr. Timothy R. Coté is a leading expert in orphan drug regulatory affairs, with 23 years of federal service, including as Director of the FDA Office of Orphan Products Development (OOPD) from 2007 to 2011. At OOPD, he implemented the Orphan Drug Act, personally signing decisions on over 1,400 orphan drug designation applications.</p>
                        </div>
                        <button class="read-more-btn" onclick="toggleBio(this)">
                            Read Full Biography <span class="arrow">→</span>
                        </button>
                        <div class="bio-full" style="display: none;">
                            <div class="bio-section">
                                <h4>A. Personal Statement</h4>
                                <p>As founder and CEO of Coté Orphan LLC, he grew a boutique firm that facilitated regulatory approvals for rare disease therapies, serving over 400 clients before its sale to QuintilesIMS in 2017. Currently, as CEO of Only Orphans Coté LLC and Partner at Porcine Preclinical Partners, Dr. Coté leverages his expertise to advance preclinical and regulatory strategies for innovative therapies. An anatomic pathologist and medical epidemiologist, he has authored 80 peer-reviewed articles on topics including HIV/AIDS-related malignancies and public health policy. For the CDKL5 gene therapy project, Dr. Coté will guide regulatory submissions, ensuring the AAV9.Syn.hCDKL5 vector meets FDA standards for IND submission, addressing the critical unmet needs of CDKL5 deficiency disorder (CDD) patients.</p>
                            </div>
                            <div class="bio-section">
                                <h4>B. Positions and Honors</h4>
                                <p><strong>Positions:</strong></p>
                                <ul>
                                    <li>2021–Present: CEO, Only Orphans Coté LLC, Cambridge, MA and Washington, DC, USA</li>
                                    <li>2022–Present: Partner, Porcine Preclinical Partners, Cambridge, MA and Ames, IA, USA</li>
                                    <li>2017–2021: Independent Entrepreneur, Self Employed, Washington DC-Baltimore Area, USA</li>
                                    <li>2017: Vice President, Quintiles (now IQVIA), Silver Spring, MD, USA</li>
                                    <li>2012–2017: Principal & CEO, Coté Orphan LLC, Silver Spring, MD, USA</li>
                                    <li>2011–2014: Professor of Regulatory Practice, Keck Graduate Institute, Claremont, CA, USA</li>
                                    <li>2011–2012: Chief Medical Officer, National Organization for Rare Disorders, USA</li>
                                    <li>2007–2011: Director, FDA Office of Orphan Products Development, FDA, USA</li>
                                    <li>2006–2007: CDC Country Director for Rwanda, Centers for Disease Control and Prevention, Rwanda</li>
                                    <li>2004–2006: Senior Federal Advisor to the Director, District of Columbia Department of Health, USA</li>
                                    <li>2002–2004: Branch Chief, Therapeutics and Blood Safety, CBER, FDA, USA</li>
                                    <li>1999–2002: Medical Director, Cancer Statistics Branch, National Cancer Institute, Rockville, MD, USA</li>
                                    <li>1998–1999: Medical Epidemiologist (PHS Detail), USDA/FSIS, USA</li>
                                    <li>1995–1998: Resident in Anatomic Pathology, National Institutes of Health, Bethesda, MD, USA</li>
                                </ul>
                            </div>
                            <div class="bio-section">
                                <h4>C. Contributions to Science</h4>
                                <p><strong>1. Advancement of Orphan Drug Development</strong></p>
                                <p>As Director of FDA's OOPD, Dr. Coté implemented the Orphan Drug Act, overseeing decisions on over 1,400 orphan drug designations. His leadership expanded therapeutic options for rare diseases, including neurological disorders like CDKL5 deficiency.</p>
                                <p><strong>2. Regulatory Innovation for Rare Diseases</strong></p>
                                <p>Through Coté Orphan LLC, Dr. Coté facilitated regulatory approvals for numerous rare disease therapies, managing submissions to FDA and EMA. His firm's work supported a significant share of orphan designations, accelerating treatments to market.</p>
                                <p><strong>3. Epidemiological Research on Public Health</strong></p>
                                <p>Dr. Coté authored 80 peer-reviewed articles, including studies on HIV/AIDS-related malignancies, typhoid fever epidemics, and bicycle helmet laws' impact on injury statistics. His work has informed public health policy and clinical practice.</p>
                                <p><strong>4. Cancer Surveillance and Data Systems</strong></p>
                                <p>As Medical Director at NCI's Cancer Statistics Branch, Dr. Coté oversaw the SEER registry, managing data from over 2 million cancer cases. He developed POPBLOCKS, the first population-based tissue collection system, enhancing cancer research capabilities.</p>
                            </div>
                        </div>
                    </div>

                </div>

                <script>
                    function toggleBio(button) {
                        const biosketch = button.closest('.biosketch-simple');
                        const fullBio = biosketch.querySelector('.bio-full');
                        const arrow = button.querySelector('.arrow');
                        
                        if (fullBio.style.display === 'none') {
                            fullBio.style.display = 'block';
                            button.innerHTML = 'Show Less <span class="arrow">↑</span>';
                            button.classList.add('active');
                        } else {
                            fullBio.style.display = 'none';
                            button.innerHTML = 'Read Full Biography <span class="arrow">→</span>';
                            button.classList.remove('active');
                        }
                    }
                </script>
            </section>
        </div>
    </main>

    <div data-include="inc/footer.html"></div>

    <script src="js/includes-loader.js" defer></script>
    <script src="js/script.js" defer></script>
    <script src="js/timeline-slider.js" defer></script>
    <script src="js/newsletter-form.js" defer></script>
</body>
</html>